Fulgent Genetics, Inc.
For the period ended Mar 31, 2025. Filed May 2, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 2, 2025
FLGT$25.78-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flow from operating activities: | ||
| Net loss from consolidated operations | $(11,899) | $(13,846) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||
| Equity-based compensation | 10,550 | 11,518 |
| Depreciation and amortization | 5,919 | 6,663 |
| Adjustment for credit losses | 2,075 | (2,497) |
| Noncash lease expense | 350 | 1,510 |
| (Gain) loss on disposal of fixed asset | (2) | 183 |
| Amortization of discount of marketable securities | (1,658) | (1,184) |
| Deferred taxes | (133) | (557) |
| Unrecognized tax benefits | 137 | — |
| Net realized loss on marketable securities | — | 580 |
| Other | 21 | (12) |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | (4,524) | 1,484 |
| Income tax | 1,761 | 5,154 |
| Other current and long-term assets | 804 | (24) |
| Accounts payable | (658) | (245) |
| Contract liabilities | 582 | (111) |
| Customer deposits | 83 | 4,547 |
| Accrued liabilities and other liabilities | (7,485) | (4,385) |
| Operating lease liabilities | (354) | (1,512) |
| Net cash (used in) provided by operating activities | (4,431) | 7,266 |
| Cash flow from investing activities: | ||
| Purchase of marketable securities | — | (195,741) |
| Purchases of fixed assets | (4,718) | (4,056) |
| Maturities of marketable securities | 32,445 | 95,450 |
| Proceeds from sale of marketable securities | — | 56,903 |
| Proceeds from sale of fixed assets | 2 | 258 |
| Net cash provided by (used in) investing activities | 27,729 | (47,186) |
| Cash flow from financing activities: | ||
| Common stock withholding for employee tax obligations | (1,887) | (1,682) |
| Repayment of notes payable | (470) | (765) |
| Principal paid for finance lease | (136) | (135) |
| Repurchase of common stock | (8,679) | (225) |
| Net cash used in financing activities | (11,172) | (2,807) |
| Effect of exchange rate changes on cash and cash equivalents | 11 | (69) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 12,137 | (42,796) |
| Cash, cash equivalents, and restricted cash at beginning of period | 55,279 | 97,473 |
| Cash, cash equivalents, and restricted cash at end of period | $67,416 | $54,677 |
| Supplemental disclosures of cash flow information: | ||
| Cash and cash equivalents | $67,281 | 54,677 |
| Restricted cash | 135 | — |
| Total cash, cash equivalents, and restricted cash | $67,416 | $54,677 |
| Income taxes paid | $54 | 1,307 |
| Interest Paid | $61 | 439 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Purchases of fixed assets in accounts payable | $2,322 | 4,739 |
| Operating lease right-of-use assets reduced due to lease modification and termination | $— | 57 |
| Sale of fixed assets in other receivable | $— | 11 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.